Jan 07, 2024
Calliditas to present at JP Morgan Healthcare Conference
Jan 07, 2024
Calliditas Therapeutics appoints Maria Törnsén as President North America
Feb 18, 2021
Calliditas Therapeutics: Year-End Report, 2020
Feb 04, 2021
First Patient Dosed in NefIgArd Open Label Extension Study
Jan 26, 2021
Calliditas Therapeutics launches proposed global offering
Jan 15, 2021
Agenda for Calliditas virtual R&D Day on January 20, 2021
Dec 16, 2020
Calliditas announces final outcome of simplified mandatory offer to the shareholders of Genkyotex
Dec 10, 2020
Calliditas wins the 2020 SwedenBio Award
Dec 09, 2020
Save the date: Calliditas to host a Capital Markets Day in Stockholm, Sweden, on January 20, 2021
Nov 27, 2020
Calliditas Therapeutics' nomination committee for the AGM 2021
Nov 12, 2020
Interim Report Q3, 2020
Nov 11, 2020
Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report
Nov 09, 2020
Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial
Sep 30, 2020
Number of shares and votes in Calliditas Therapeutics
Sep 08, 2020
First patient in China enrolled in clinical phase 3 study NefIgArd with lead candidate Nefecon
Aug 25, 2020
Calliditas appoints Group General Counsel
Aug 13, 2020
Calliditas Therapeutics: Interim Report Q2, 2020
Aug 13, 2020
Calliditas Announces Agreement to Acquire Controlling Interest in Genkyotex SA
Aug 11, 2020
Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q2 report
Jul 24, 2020
Calliditas reorganizes its management team